<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Brimonidine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00484</strong>&#160; (APRD00034)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Brimonidine is a drug used to treat glaucoma. It acts via decreasing aqueous humor synthesis. [Wikipedia] A topical gel formulation, marketed under the name Mirvaso, was <span class="caps">FDA</span> approved on August 2013 for the treatment of rosacea.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00484/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00484/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00484.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00484.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00484.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00484.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00484.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00484">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Bromoxidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Brimonidine Tartrate</strong>
          <div class="cas">70359-46-5</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000195/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000195/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: QZHBYNSSDLTCRG-LREBCSMRSA-N</li>
              <li>Monoisotopic Mass: 441.028395916</li>
              <li>Average Mass: 442.221</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000195">DBSALT000195</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alphagan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mirvaso</td><td>Galderma Laboratories, L.P.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Combigan</td><td>Brimonidine and Timolol </td></tr><tr><td>Simbrinza</td><td>Brimonidine and Brinzolamide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/adrenergic-alpha-2-receptor-agonists">Adrenergic alpha-2 Receptor Agonists</a></li>
<li><a href="/mesh/eent-preparations">EENT Preparations</a></li></ul></td></tr><tr><th>CAS number</th><td>59803-98-4</td></tr><tr><th>Weight</th><td>Average: 292.135<br>Monoisotopic: 291.011957992</td></tr><tr><th>Chemical Formula</th><td>C<sub>11</sub>H<sub>10</sub>BrN<sub>5</sub></td></tr><tr><th>InChI Key</th><td>XYLJNLCSTIOKRM-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Naphthyridines</td></tr><tr><th>Subclass</th><td>Quinoxalines</td></tr><tr><th>Direct parent</th><td>Quinoxalines</td></tr><tr><th>Alternative parents</th><td>Bromobenzenes; Pyrazines; Aryl Bromides; Guanidines; Polyamines; Organobromides</td></tr><tr><th>Substituents</th><td>bromobenzene; aryl halide; benzene; aryl bromide; pyrazine; guanidine; polyamine; organobromide; organohalogen; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older. </td></tr><tr><th>Pharmacodynamics</th><td>Brimonidine significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. It lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.</td></tr><tr><th>Mechanism of action</th><td>Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction. </td></tr><tr><th>Absorption</th><td>Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 &#177; 62 pg/mL and 417 &#177; 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized primarily by the liver.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Brimonidine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003539" target="_blank">Aldehyde oxidase</a></li></ul></td><td><a href="/metabolites/DBMET00464">2-oxobrimonidine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/473">Details</a></td></tr><tr><td>Brimonidine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003539" target="_blank">Aldehyde oxidase</a></li></ul></td><td><a href="/metabolites/DBMET00465">3-oxobrimonidine </a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/474">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Urinary excretion is the major route of elimination of the drug and its metabolites.</td></tr><tr><th>Half life</th><td>2 hours [ophthalmic solution]  </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral LD<sub>50</sub> is 50 mg/kg in mice and 100 mg/kg in rats. Common adverse reactions of the topical gel formulation include erythema, flushing, skin burning sensation, and contact dermatitis. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.978</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.717</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5435</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7017</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5688</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5951</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.8266</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8403</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7533</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5617</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6898</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7044</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8222
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9446
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0196 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8093
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6711
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Allergan inc</li>
<li>Allergan</li>
<li>Akorn inc</li>
<li>Alcon inc</li>
<li>Alcon research ltd</li>
<li>Bausch and lomb pharmaceuticals inc</li>
<li>Sandoz canada inc</li>
<li>Teva parenteral medicines inc</li>
<li>Allergan, Inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.alcon.com">Alcon Laboratories</a></li>
<li><a href="http://www.allergan.com">Allergan Inc.</a></li>
<li><a href="http://www.bausch.com">Bausch &amp; Lomb Inc.</a></li>
<li><a href="http://www.falconpharma.com">Falcon Pharmaceuticals Ltd.</a></li>
<li>Ivax Pharmaceuticals</li>
<li>Pacific Pharma Lp</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Gel</td><td>Topical</td><td>0.33%</td></tr><tr><td>Solution</td><td>Ophthalmic</td><td>0.1%, 0.15%</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00601">Linezolid</a></td><td>MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification. </td></tr><tr><td><a href="/drugs/DB01171">Moclobemide</a></td><td>MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>MAO Inhibitors like phenelzine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB01168">Procarbazine</a></td><td>MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB01367">Rasagiline</a></td><td>MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB01037">Selegiline</a></td><td>MAO Inhibitors like selegiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Brimonidine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>